Ann: Net Tangible Asset Backing-NEN.AX, page-5

First 5 Last

1234zxcv

374 Posts.

04/05/16

11:29

Post #: 17672729

Originally posted by rich0man ↑

Cash backing of 35cents and present price is 24.5 cents.
Now announce another buy back of 10% of shares issued.
Therefore ... would that then take Evoworlds shareholdings up by 1o% to 44% because of less shares on issue ... ?
$18 million in the bank and paying directors good salaries to do nothing or is it a cash grab by stealth ... or DEJAVU .. SEE what happened at INDAGO RESOURCES below.

Column 1

1 Evoworld has specifically stated that it will seek to reduce corporate overheads. However, this does not seem consistent with what occurred in relation to Indago Resources Limited, one of the companies Evoworld cites as an example of a recent successful transaction its directors have been involved in. To quote a report in the WA Business News in 2010 on cash and equity remuneration paid to directors of WA companies:
Messrs [Timothy] Kestell and [Peter] Pynes each received just less than $6.05 million for the year [FY2010], notwithstanding Indago’s negative one-year TSR of 25 per cent.
The report also noted that Messrs Kestell and Pynes were the fourth and fifth highest paid executives in the survey done by the WA Business News.
The total remuneration (including equity payments) paid by Indago to Messrs Kestell and Pynes during the financial year ended 30 June 2010 was almost $12.1 million, when Indago’s market capitalisation as at 30 June 2010 was $40.28 million

ARE YOU WATCHING ASX ???

Expand

Keep them on their toes and vote against the remuneration report at the AGM. It will be the only chance to get a strike against them

NEN Price at posting: 25.0¢ Sentiment: Hold Disclosure: Held

1 Upvote

0 Great analysis

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

FFM

Firefly positioned for copper growth in Canada ahead of resource update

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger